Analysts Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Target Price at $37.81

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been given a consensus recommendation of “Moderate Buy” by the seventeen research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and three have given a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $36.1333.

DYN has been the topic of several recent research reports. Evercore dropped their price target on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, December 15th. Morgan Stanley lowered their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday. Robert W. Baird set a $30.00 target price on Dyne Therapeutics in a report on Monday, December 8th. HC Wainwright cut their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, JPMorgan Chase & Co. decreased their price target on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th.

Dyne Therapeutics Trading Down 2.2%

DYN stock traded down $0.34 during midday trading on Friday, hitting $14.86. The stock had a trading volume of 2,592,773 shares, compared to its average volume of 1,751,362. The firm has a market cap of $2.45 billion, a P/E ratio of -4.20 and a beta of 1.34. The company has a current ratio of 22.25, a quick ratio of 13.47 and a debt-to-equity ratio of 0.15. Dyne Therapeutics has a 1-year low of $6.36 and a 1-year high of $25.00. The business has a fifty day moving average price of $17.05 and a two-hundred day moving average price of $17.05.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). On average, sell-side analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC purchased a new stake in Dyne Therapeutics in the first quarter worth $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Dyne Therapeutics by 5.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after buying an additional 2,886 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Dyne Therapeutics by 58.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after acquiring an additional 366,183 shares during the period. Caxton Associates LLP bought a new position in shares of Dyne Therapeutics during the 1st quarter worth $157,000. Finally, CWM LLC increased its holdings in Dyne Therapeutics by 168.1% in the 2nd quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after acquiring an additional 1,900 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Key Stories Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $50 price target and is projecting strong long‑term recovery (FY2030 EPS of $3.24), signaling meaningful upside in the firm’s model beyond the next several years. MarketBeat Report
• Positive Sentiment: HC Wainwright modestly improved its FY2026 estimate (less negative: from ($3.17) to ($3.05)), which slightly reduces short‑term downside in the firm’s forecasts. MarketBeat Report
• Neutral Sentiment: Analysts from both firms largely converged on near‑term quarterly guidance (many quarters forecast around ($0.76) EPS), and the street consensus full‑year loss remains near ($3.44) — this keeps near‑term expectations stable even as individual line‑items shift. MarketBeat Report
• Neutral Sentiment: Short‑interest data reported for early March appears anomalous (shows zero shares / NaN changes), so the print is likely a reporting glitch and not actionable market pressure. MarketBeat Report
• Negative Sentiment: HC Wainwright reduced FY2028 and FY2029 EPS forecasts (FY2028 to ($0.08) from $0.11; FY2029 to $1.28 from $1.56) and nudged FY2027 slightly lower — these downward revisions compress medium‑term earnings visibility and likely weigh on sentiment. MarketBeat Report
• Negative Sentiment: Lifesci Capital trimmed several near‑term quarterly EPS estimates (Q4 2026 to ($0.86) from ($0.85); Q2 2026 to ($0.79) from ($0.77)), modestly increasing expected near‑term losses and adding short‑term pressure. MarketBeat Report

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.